Patent Examiner John S. Kenyon
Art Unit 1625 · Heterocyclic Drug Compounds & Medicinal Chemistry · Tech Center 1600 · 378 applications filed 2021–2026
John S. Kenyon is a USPTO patent examiner in Art Unit 1625 (Heterocyclic Drug Compounds & Medicinal Chemistry) with 378 applications from filing years 2021–2026. Examiner Kenyon's allowance rate is 68.4%, below the 82.2% USPTO average for applications filed in the same years. The examiner ranks harder than 75% of examiners. In 2021, decided applications with an examiner interview were allowed 29.1 percentage points more often than those without.
Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology
Overview
FreeExaminer details
- Art unit1625 · Heterocyclic Drug Compounds & Medicinal Chemistry
- Title / gradePrimary Patent Examiner · GS-14
- Service14 years
- PhoneOn each office action
- Email[email protected]
- In USPTO recordsKENYON, JOHN S
Examiner Kenyon can allow an application without a supervisory sign-off.
How to improve your odds with Examiner Kenyon
- The data favors an interview. Interviewed cases were allowed more often in both measured years, by 29.1 to 32.6 points.
- Plan for the timeline. First office action averages 778 days vs the 624-day USPTO norm.
- Expect a §112. Definiteness & disclosure is the most-issued rejection (134), and applicants overcame it 79.0% of the time.
- The data favors an RCE here. Cases with an RCE were allowed more often in both measured years, by 9.6 to 34.1 points.
Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.
Rejection patterns & how they get overcome
FreeOf the 55 winning responses to Examiner Kenyon's §112 rejections that Boundly has classified, 29 (53%) amended the claims and argued, 25 amended without arguing, and 1 argued without amending. Each winning response, with its arguments and claim amendments, is in the file wrapper.
Just got an office action from Examiner Kenyon?
Draft your response with Examiner Kenyon's record and Art Unit 1625's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See the office action response workflow.
Trends
| Year | Interview rate | Allowance w/ interview | Allowance w/o | Delta |
|---|---|---|---|---|
| 2022 | 6.4% | 100.0% | 67.4% | +32.6pp |
| 2021 | 9.2% | 88.9% | 59.8% | +29.1pp |
RCE behavior
Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Kenyon.
| Year | RCE rate | Allowance w/ RCE | Allowance w/o | Delta |
|---|---|---|---|---|
| 2022 | 11.0% | 100.0% | 65.9% | +34.1pp |
| 2021 | 8.2% | 71.4% | 61.8% | +9.6pp |
Recent outcomes
Free🔒 Case detail for members| App # | Title | Outcome | OAs | Arguments & redline |
|---|---|---|---|---|
| 18/606590 | Methods for Treating Cancer | Patented | 1 | 🔒 View |
| 18/559288 | Heterocyclic TRPML1 Agonists and Uses Thereof | Patented | 0 | 🔒 View |
| 18/557919 | Xanthine Oxidase Inhibitor | Patented | 0 | 🔒 View |
| 18/311744 | Process for the Purification of Mitragynine | Patented | 1 | 🔒 View |
Art Unit 1625 technology
Frequently asked questions
What is Examiner John S. Kenyon's allowance rate?
Is Examiner Kenyon a hard examiner?
Do examiner interviews help with Examiner Kenyon?
What is Examiner Kenyon's most common rejection?
Is an RCE worth filing with Examiner Kenyon?
How long until the first office action from Examiner Kenyon?
How do I contact Examiner John S. Kenyon?
Put Examiner Kenyon's data to work on your next response.
Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.